ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of “Moderate Buy” by Analysts

ADC Therapeutics SA (NYSE:ADCT) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $7.50.

A number of analysts have recently issued reports on the stock. Guggenheim reaffirmed a “buy” rating and set a $10.00 price target on shares of ADC Therapeutics in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of ADC Therapeutics in a report on Wednesday, October 8th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $5.00 target price on shares of ADC Therapeutics in a research report on Wednesday, December 3rd. HC Wainwright lowered their price target on ADC Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, October 16th. Finally, Wall Street Zen upgraded ADC Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th.

Institutional Investors Weigh In On ADC Therapeutics

Large investors have recently made changes to their positions in the company. R Squared Ltd bought a new position in shares of ADC Therapeutics in the 3rd quarter worth approximately $59,000. Henrickson Nauta Wealth Advisors Inc. bought a new position in ADC Therapeutics in the fourth quarter worth approximately $69,000. SG Americas Securities LLC purchased a new position in shares of ADC Therapeutics during the 4th quarter worth $86,000. Creative Planning bought a new stake in shares of ADC Therapeutics during the 2nd quarter valued at $96,000. Finally, Ethic Inc. purchased a new stake in shares of ADC Therapeutics in the 2nd quarter worth $103,000. 41.10% of the stock is currently owned by institutional investors.

ADC Therapeutics Trading Up 1.7%

ADC Therapeutics stock opened at $3.61 on Tuesday. ADC Therapeutics has a 12 month low of $1.05 and a 12 month high of $4.80. The stock has a fifty day simple moving average of $3.84 and a two-hundred day simple moving average of $3.61. The firm has a market cap of $447.21 million, a price-to-earnings ratio of -2.49 and a beta of 1.95.

ADC Therapeutics (NYSE:ADCT) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.10. The business had revenue of $16.43 million for the quarter, compared to analysts’ expectations of $17.08 million. On average, equities research analysts forecast that ADC Therapeutics will post -1.69 EPS for the current fiscal year.

ADC Therapeutics Company Profile

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.